ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DRS Drs Data&Rsrch

19.50
0.00 (0.00%)
20 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Drs Data&Rsrch LSE:DRS London Ordinary Share GB0002502580 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 19.50 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

DRS Data & Research Services PLC Release of capitalised development expenditure (1508M)

18/01/2016 10:02am

UK Regulatory


Drs Data&Rsrch (LSE:DRS)
Historical Stock Chart


From Mar 2020 to Mar 2025

Click Here for more Drs Data&Rsrch Charts.

TIDMDRS

RNS Number : 1508M

DRS Data & Research Services PLC

18 January 2016

DRS Data and Research Services plc

(the "Group" or "DRS") (LSE: DRS)

Release of capitalised development expenditure

Historically, development expenditure relating to the new e-Marker(R) examination software product has been capitalised on the balance sheet in accordance with the requirements of IAS38 'Intangible Assets'. A year-end review has led the Group to conclude that under IAS38, the previously capitalised expenditure of GBP2,770,000 built up since May 2012 should be expensed to the Income Statement as the criteria for capitalisation are no longer met. The need to develop a broader set of features to meet market needs, combined with increasingly challenging international market conditions, have resulted in the deferral of projected annual revenue expectations which are used to support the carrying value of the asset, hence this resultant change in accounting treatment.

This change will result in future expenditure on development of the new e-Marker(R) product being charged to the Income Statement as it is incurred.

The Group remains committed to the development of its e-Marker(R) examination software products.

Enquiries to:

Richard Cole

Company Secretary

Tel: 01908 666088

enquiries@drs.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCKVLBFQFFEBBD

(END) Dow Jones Newswires

January 18, 2016 05:02 ET (10:02 GMT)

1 Year Drs Data&Rsrch Chart

1 Year Drs Data&Rsrch Chart

1 Month Drs Data&Rsrch Chart

1 Month Drs Data&Rsrch Chart